Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + docetaxel + trastuzumab
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves **capecitabine**, a tumor-activated oral fluoropyrimidine; **docetaxel**, a taxane chemotherapy drug; and **trastuzumab**, a monoclonal antibody targeting HER2-positive cancers. It is used in the treatment of HER2-positive advanced gastric cancer and metastatic breast cancer. The combination aims to enhance efficacy by targeting different pathways involved in cancer progression.
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)Microtubule
Beyond the preview
Go deeper on capecitabine + docetaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + docetaxel + trastuzumab.